

## Amendments

### In the Claims

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Claims 1, 8, 9, 12-17, and 39-48 are pending in this Application.


Claims 2-7, 10-11, and 18-38 were previously canceled.

Claims 24-30 are withdrawn from consideration but are subject to rejoinder.

Claims 1, 9, 12, 13, and 40-43 are currently amended.

Claims 8, 14-17, 39, and 44-48 were previously presented.

1. **(currently amended)** A compound represented by formula I,



or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof, and wherein,

each W is CR<sup>1</sup>;

each R<sup>1</sup> is independently selected from -H and -A-R<sup>7</sup>; provided one of R<sup>1</sup> is -A-R<sup>7</sup> and is located at the 5-position of the indolinone ring, wherein, only for said -A-R<sup>7</sup>, R<sup>7</sup> must be a piperidin-4-yl, and where the nitrogen of the piperidin-4-yl of -A-R<sup>7</sup> is optionally substituted with one group selected from alkyl, ~~aryl~~, arylalkyl, ~~heterocyclylalkyl~~, ~~pyrrolidinylethyl~~, ~~piperidinylethyl~~, ~~morpholinylethyl~~, ~~heterocyclyl~~, ~~acyl~~, and sulfonyl[[, ]];

A is NH;

L is NR<sup>3</sup>;

Q is C;

$R^2$  and  $R^3$  are each -H;

$R^4$  and  $R^5$  are each independently selected from -H,  $-OR^6$ ,  $-NR^6R^7$ ,  $-S(O)_{0-2}R^6$ ,  $-SO_2NR^6R^7$ ,  $-CO_2R^6$ ,  $-C(O)NR^6R^7$ ,  $-N(R^6)SO_2R^6$ ,  $-C(O)R^7$ , -CN,  $-NO_2$ ,  $-NH_2$ , halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl- $R^7$ ; or


$R^4$  and  $R^5$ , when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of  $R^{15}$ ;

$R^6$  is selected from -H, and  $C_{1-8}$ alkyl, aryl,  $C_{1-8}$ alkyl, heterocyclyl,  $C_{1-8}$ alkyl, aryl, and heterocyclyl;

$R^7$ , for other than  $R^7$  in  $-A-R^7$ , is selected from -H, and  $C_{1-8}$ alkyl, aryl,  $C_{1-8}$ alkyl, heterocyclyl,  $C_{1-8}$ alkyl, aryl, heterocyclyl; provided that there are at least two carbons between any heteroatom of  $R^7$  and either nitrogen to which  $R^2$  and  $R^3$  are attached; [[or]]

$R^8$  is -H,  $-NO_2$ , -CN,  $-OR^6$ , or [[and ]]  $C_{1-8}$ alkyl;

X is selected from one of the following [[six ]] formulae:



wherein m is zero to five, n is zero to three, and Z is  $CR^{10}$ ;


$R^{10}$  is selected from -H, halogen, trihalomethyl,  $-NH_2$ ,  $-NO_2$ ,  $-OR^6$ ,  $-N=CNR^6R^7$ ,  $-NR^6R^7$ ,  $-N(R^6)C(=NR^8)NR^6R^7$ ,  $-SR^6$ ,  $-S(O)_{1-2}R^6$ ,  $-SO_2NR^6R^7$ ,  $-CO_2R^6$ ,  $-C(O)NR^6R^7$ ,  $-C(O)N(OR^6)R^7$ ,  $-C(=NR^8)NR^6R^7$ ,  $-N(R^6)SO_2R^6$ ,  $-C(O)R^7$ , and  $R^7$ ;

K is O; and

each  $R^{15}$  is independently selected from -H, halogen,  $-OR^6$ , and  $C_{1-8}$ alkyl- $NH_2$ ,  $-NO_2$ ,  $-OR^6$ ,  $-N=CNR^6R^7$ ,  $-NR^6R^7$ ,  $-N(R^6)C(=NR^8)NR^6R^7$ ,  $-SR^6$ ,  $-S(O)_{1-2}R^6$ ,  $-SO_2NR^6R^7$ ,  $-CO_2R^6$ ,  $-C(O)NR^6R^7$ ,  $-C(O)N(OR^6)R^7$ ,  $-C(=NR^8)NR^6R^7$ ,  $-N(R^6)SO_2R^6$ ,  $-C(O)R^7$ , and  $R^7$ .


Claims 2-7 (previously canceled)

8. (previously presented) The compound according to claim 1, wherein X is



m is 0 to 3, and  $R^{10}$  is selected from -H, halogen,  $-NH_2$ ,  $-NO_2$ ,  $-OR^6$ ,  $-N=CNR^6R^7$ ,  $-NR^6R^7$ ,  $-N(R^6)C(=NR^8)NR^6R^7$ ,  $-SR^6$ ,  $-S(O)_{1-2}R^6$ ,  $-SO_2NR^6R^7$ ,  $-CO_2R^6$ ,  $-C(O)NR^6R^7$ ,  $-C(O)N(OR^6)R^7$ ,  $-C(=NR^8)NR^6R^7$ ,  $-N(R^6)SO_2R^6$ ,  $-C(O)R^7$ , and  $-C_{1-8}alkyl$ ; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

9. (currently amended) A compound of formula II:



II

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein:

A is  $NH$ ;

$R^7$ , in  $-A-R^7$ , is piperidin-4-yl and is located on the 5-position of the indolinone ring; wherein the ring nitrogen of  $R^7$  is substituted with a group  $R^{12}$ ; and

$R^{12}$  is selected from a) -H, b)  $C_{1-8}alkyl$ , c)  $-SO_2R^6$ , d)  $-SO_2NR^6R^7$ , e)  $-CO_2R^6$ , f)  $-C(O)NR^6R^7$ , and g)  $-C(O)R^7$ ; and where the  $C_{1-8}alkyl$  in b) is optionally substituted with one to five groups independently selected from alkyl, aryl, arylalkyl, ~~heterocyclylalkyl~~, ~~heterocyclyl~~, ~~pyrrolidinylethyl~~, ~~piperidinylethyl~~, ~~morpholinylethyl~~, alkoxy, ~~substituted alkoxy~~, ~~amino~~, ~~alkylamino~~, ~~and dialkylamino~~, ~~amidino~~, ~~aryloxy~~, ~~arylalkyloxy~~, ~~carboxy~~,

~~acyloxy, benzyloxycarbonylamino, cyano, acyl, halogen, hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, oxo, carbamyl, and acylamino;~~

R<sup>6</sup> is selected from -H and C<sub>1-8</sub>alkyl;

R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H, -OR<sup>6</sup>, -NR<sup>6</sup>R<sup>7</sup>, -S(O)<sub>0-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl-R<sup>7</sup>; or

R<sup>4</sup> and R<sup>5</sup>, when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of R<sup>15</sup>;

R<sup>10</sup> is selected from -H, halogen, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>, and C<sub>1-8</sub>alkyl;

m is 0 to 3;


R<sup>7</sup>, for other than R<sup>7</sup> in A-R<sup>7</sup>, is selected from -H, and C<sub>1-8</sub>alkyl, ~~arylC<sub>1-8</sub>alkyl~~, ~~heterocyclylC<sub>1-8</sub>alkyl~~, and ~~heterocyclyl~~;

R<sup>8</sup> is -H, -NO<sub>2</sub>, -CN, -OR<sup>6</sup>, or [[and]] C<sub>1-8</sub>alkyl; and

each R<sup>15</sup> is independently selected from -H, halogen, -OR<sup>6</sup>, and C<sub>1-8</sub>alkyl-NH<sub>2</sub>, ~~NO<sub>2</sub>~~, ~~OR<sup>6</sup>~~, ~~N=CNR<sup>6</sup>R<sup>7</sup>~~, ~~NR<sup>6</sup>R<sup>7</sup>~~, ~~N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>~~, ~~SR<sup>6</sup>~~, ~~S(O)<sub>1-2</sub>R<sup>6</sup>~~, ~~SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>~~, ~~CO<sub>2</sub>R<sup>6</sup>~~, ~~C(O)NR<sup>6</sup>R<sup>7</sup>~~, ~~C(O)N(OR<sup>6</sup>)R<sup>7</sup>~~, ~~C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>~~, ~~N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>~~, ~~C(O)R<sup>7</sup>~~, and R<sup>7</sup>.

Claims 10-11 (previously canceled)

12. (currently amended) A compound according to formula III.



III

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

where

$R^{12}$  is a  $C_{1-4}$ alkylene;

$R^{13}$  is selected from -H, an alkoxy group, amino, alkylamino, dialkylamino, pyrrolidinylethyl, piperidinylethyl, and morpholinylethyl, ~~and an heterocyclyl~~, with the proviso that a heteroatom of said alkoxy group, amino group, alkylamino group, and dialkylamino group, ~~and heterocyclyl~~ cannot be attached to a carbon of  $R^{12}$  which is directly attached to the ring nitrogen of the piperidine in formula III;

$R^4$  and  $R^5$  are each independently selected from -H,  $-OR^6$ ,  $-NR^6R^7$ ,  $-S(O)_{0-2}R^6$ ,  $-SO_2NR^6R^7$ ,  $-CO_2R^6$ ,  $-C(O)NR^6R^7$ ,  $-N(R^6)SO_2R^6$ ,  $-C(O)R^7$ , -CN,  $-NO_2$ ,  $-NH_2$ , halogen, trihalomethyl, alkyl, 1,3-dioxo-isoindol-2-ylethyl, and aryl- $R^7$ ; or

$R^4$  and  $R^5$ , when taken together, form a six-membered aromatic ring system containing zero nitrogens, said six-membered aromatic ring system is optionally substituted with between zero and four of  $R^{15}$ ;

$R^6$  is selected from -H and  $C_{1-8}$ alkyl;

$R^7$  is selected from -H, and  $C_{1-8}$ alkyl, ~~aryl $C_{1-8}$ alkyl, heterocyclyl $C_{1-8}$ alkyl, aryl, and heterocyclyl~~;


$R^8$  is -H,  $-NO_2$ , -CN,  $-OR^6$ , or ~~or~~  $[[\text{and}]]C_{1-8}$ alkyl;

$R^{10}$  is selected from -H, halogen,  $-NH_2$ ,  $-NO_2$ ,  $-OR^6$ ,  $-N=CNR^6R^7$ ,  $-NR^6R^7$ ,  $-N(R^6)C(=NR^8)NR^6R^7$ ,  $-SR^6$ ,  $-S(O)_{1-2}R^6$ ,  $-SO_2NR^6R^7$ ,  $-CO_2R^6$ ,  $-C(O)NR^6R^7$ ,  $-C(O)N(OR^6)R^7$ ,  $-C(=NR^8)NR^6R^7$ ,  $-N(R^6)SO_2R^6$ ,  $-C(O)R^7$ , and  $C_{1-8}$ alkyl;

m is 0 to 3; and

each  $R^{15}$  is independently selected from -H, halogen,  $-OR^6$ , and  $C_{1-8}$ alkyl- $NH_2$ ,  ~~$-NO_2$ ,  $-OR^6$ ,  $-N=CNR^6R^7$ ,  $-NR^6R^7$ ,  $-N(R^6)C(=NR^8)NR^6R^7$ ,  $-SR^6$ ,  $-S(O)_{1-2}R^6$ ,  $-SO_2NR^6R^7$ ,  $-CO_2R^6$ ,  $-C(O)NR^6R^7$ ,  $-C(O)N(OR^6)R^7$ ,  $-C(=NR^8)NR^6R^7$ ,  $-N(R^6)SO_2R^6$ ,  $-C(O)R^7$ , and  $R^7$ .~~

13. (currently amended) A compound according to formula **IIIa**,



**IIIa**

or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof;

wherein  $R^{12}$  is a  $C_{2-4}$ alkylene;

$R^{13}$  is selected from -H, an alkoxy group, an amino group, an alkylamino group, a dialkylamino group pyrrolidinylethyl, piperidinylethyl, and morpholinylethyl; and an ~~heteroalkylethyl~~;

$R^{10}$  is selected from -H, halogen, perfluoroalkyl, -NH<sub>2</sub>, -NO<sub>2</sub>, -OR<sup>6</sup>, -N=CNR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -SR<sup>6</sup>, -S(O)<sub>1-2</sub>R<sup>6</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CO<sub>2</sub>R<sup>6</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -C(O)N(OR<sup>6</sup>)R<sup>7</sup>, -C(=NR<sup>8</sup>)NR<sup>6</sup>R<sup>7</sup>, -N(R<sup>6</sup>)SO<sub>2</sub>R<sup>6</sup>, -C(O)R<sup>7</sup>;

$R^4$  and  $R^5$  are each independently selected from -H, halogen, and  $C_{1-4}$ alkyl; or  $R^4$  and  $R^5$  combined are a phenyl where the phenyl is optionally substituted with one to five groups independently selected from alkyl, ~~aryl, arylalkyl, heterocyclylalkyl, heterocyclyl,~~ alkoxy, ~~substituted alkoxy, methylenedioxy, amino, alkylamino, dialkylamino, amidino,~~ aryloxy, ~~arylalkyloxy, carboxy, acyloxy, benzyloxy, carbonylamino, cyano, acyl, and~~ halogen, ~~hydroxy, nitro, sulfanyl, sulfinyl, sulfonyl, halogen, hydroxy, carbamyl, and~~ acylamino;

m is 0-3;

$R^6$  is selected from -H and  $C_{1-8}$ alkyl, ~~said  $C_{1-8}$ alkyl substituted with at least one of -CO<sub>2</sub>H and -CO<sub>2</sub> $C_{1-8}$ alkyl;~~

$R^7$  is selected from -H, and  $C_{1-8}$ alkyl, ~~aryl $C_{1-8}$ alkyl, heterocyclyl $C_{1-8}$ alkyl, aryl, and~~ heterocyclyl; and

$R^8$  is -H, -NO<sub>2</sub>, -CN, -OR<sup>6</sup>, or ~~or~~  $C_{1-8}$ alkyl.

14. **(previously presented)** The compound according to claim 13, wherein R<sup>12</sup> is an ethylene; R<sup>10</sup> is halogen; R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H, halogen, and C<sub>1-2</sub>alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

15. **(previously presented)** The compound according to claim 14, wherein each R<sup>10</sup> is independently selected from fluorine and chlorine; R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H and C<sub>1-2</sub>alkyl; and m is 1-3; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

16. **(previously presented)** The compound according to claim 15, wherein each R<sup>10</sup> is independently selected from fluorine and chlorine; R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H and -CH<sub>3</sub>; and m is 1-2; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

17. **(previously presented)** The compound according to claim 16, wherein R<sup>10</sup> is fluorine; R<sup>4</sup> and R<sup>5</sup> are each independently selected from -H and -CH<sub>3</sub>; and m is 1; or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof; and where the compound is optionally as a pharmaceutically acceptable salt thereof.

Claims 18-38 **(previously canceled)**

39. **(previously presented)** The compound according to claim 17, selected from:

49	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
51	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
58	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
70	(3Z)-3-[(3-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
78	(3Z)-3-[(4-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one

82	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-piperidin-1-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one;
83	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-morpholin-4-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one;
84	(3Z)-5-([1-[2-(diethylamino)ethyl]piperidin-4-yl]amino)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
85	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(2-pyrrolidin-1-ylethyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one;
106	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
107	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(2-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; and
113	(3Z)-3-[(2-fluorophenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

40. (currently amended) The Compound of Claim 9 selected from

22	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one;
28	<u>2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione;</u>
30	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[[1-(methylsulfonyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one;
81	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-(piperidin-4-ylamino)-1,3-dihydro-2H-indol-2-one; and
93	(3Z)-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-5-[[1-(methylsulfonyl)piperidin-4-yl]amino]-1,3-dihydro-2H-indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

41. (currently amended) The compound of Claim 12 selected from

4	(3Z)-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-5-[[1-(phenylmethyl)pyrrolidin-3-yl]amino]-1,3-dihydro-2H-indol-2-one;
6	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
12	(3Z)-3-[1H-benzimidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
13	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
14	(3Z)-5-[(1-ethylpiperidin-4-yl)oxy]-3-[[5-(methoxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
28	<u>2-(2-{2-[(Z)-{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3H-indol-3-ylidene}(phenyl)methyl]-1H-imidazol-4-yl}ethyl)-1H-isoindole-1,3(2H)-dione;</u>
50	(3Z)-3-[1H-benzimidazol-2-yl(3-fluoro-4-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;

52	(3Z)-3-[1H-benzimidazol-2-yl(4-fluoro-3-methylphenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
57	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
59	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
63	(3Z)-3-[(3-fluoro-4-methylphenyl)(1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
64	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
67	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
69	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
77	(3Z)-3-[(4-methyl-1H-imidazol-2-yl)(4-methylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
86	(3Z)-3-[1H-imidazol-2-yl(4-methylphenyl)methylidene]-5-[(1-methylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
88	ethyl 2-((Z)-(3-fluorophenyl)[5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-2-oxo-1,2-dihydro-3H-indol-3-ylidene]methyl)-4-methyl-1H-imidazole-5-carboxylate;
94	(3Z)-3-[1H-imidazol-2-yl(4-propylphenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;
95	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;
96	(3Z)-3-[(3-fluorophenyl)(4-phenyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one; and
97	(3Z)-3-[(3-fluoro-4-methylphenyl)(4-methyl-1H-imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2H-indol-2-one;

and where the compound is optionally as a pharmaceutically acceptable salt thereof.

42. (currently amended) The compound of Claim 13 selected from

3	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[[5-(methyloxy)-1H-benzimidazol-2-yl](phenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
4	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[1H-imidazol-2-yl(phenyl)methylidene]-1,3-dihydro-2H-indol-2-one;
5	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{{5-(methyloxy)-1H-benzimidazol-2-yl}[4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2H-indol-2-one;
7	(3Z)-3-[1H-benzimidazol-2-yl(4-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
8	(3Z)-3-{1H-benzimidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;
9	(3Z)-3-[1H-benzimidazol-2-yl(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2H-indol-2-one;

11	(3Z)-3-[(4-aminophenyl)(1 <i>H</i> -benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
15	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1 <i>H</i> -imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-1,3-dihydro-2 <i>H</i> -indol-2-one;
16	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
17	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
18	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
19	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-nitrophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
21	(3Z)-3-[(3-aminophenyl)(1 <i>H</i> -benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
23	3-(( <i>Z</i> )-1 <i>H</i> -benzimidazol-2-yl{5-[(1-ethylpiperidin-4-yl)amino]-2-oxo-1,2-dihydro-3 <i>H</i> -indol-3-ylidene}methyl)benzenecarboximidamide;
24	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
26	(3Z)-3-{1 <i>H</i> -benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
27	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
29	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(phenyl)methylidene]-5-({1-[2-(dimethylamino)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
38	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-chlorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
39	(3Z)-3-{1 <i>H</i> -benzimidazol-2-yl[3-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
42	<u>(3Z)-3-[1<i>H</i>-benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2<i>H</i>-indol-2-one</u>
45	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(4-chlorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
46	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(3-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
47	(3Z)-3-[1 <i>H</i> -benzimidazol-2-yl(4-fluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
55	(3Z)-3-[(5-chloro-1 <i>H</i> -benzimidazol-2-yl)(phenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
56	(3Z)-3-[(5-chloro-1 <i>H</i> -benzimidazol-2-yl)(3,5-difluorophenyl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
60	(3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1 <i>H</i> -imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-1,3-dihydro-2 <i>H</i> -indol-2-one;
61	(3 <i>E</i> )-3-[(3,5-difluorophenyl)(5-fluoro-1 <i>H</i> -benzimidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
62	(3Z)-3-[(3,5-difluorophenyl)(5-fluoro-1 <i>H</i> -benzimidazol-2-yl)methylidene]-5-[(1-

	ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
65	(3 <i>Z</i> )-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1 <i>H</i> -imidazol-2-yl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
71	(3 <i>Z</i> )-3-{1 <i>H</i> -imidazol-2-yl[4-(trifluoromethyl)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
72	(3 <i>Z</i> )-3-[(5-chloro-1 <i>H</i> -benzimidazol-2-yl)(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
89	(3 <i>Z</i> )-3-[1 <i>H</i> -imidazol-2-yl(phenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
90	(3 <i>Z</i> )-3-{1 <i>H</i> -imidazol-2-yl[4-(methyloxy)phenyl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
92	(3 <i>Z</i> )-3-[[3-fluoro-4-(trifluoromethyl)phenyl](1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one;
100	(3 <i>Z</i> )-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](1 <i>H</i> -imidazol-2-yl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
101	(3 <i>Z</i> )-5-[(1-ethylpiperidin-4-yl)amino]-3-[(4-methyl-1 <i>H</i> -imidazol-2-yl)[4-(trifluoromethyl)phenyl]methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
103	(3 <i>Z</i> )-5-[(1-ethylpiperidin-4-yl)amino]-3-[[3-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
108	(3 <i>Z</i> )-5-[(1-ethylpiperidin-4-yl)amino]-3-[[2-fluoro-4-(trifluoromethyl)phenyl](4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-1,3-dihydro-2 <i>H</i> -indol-2-one;
114	(3 <i>Z</i> )-3-[(3-trifluoromethylphenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
115	(3 <i>Z</i> )-3-[(3-trifluoromethylphenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;
116	(3 <i>Z</i> )-3-[(2,4-dichloro-5-fluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one; and
117	(3 <i>Z</i> )-3-[(2,4-dichloro-5-fluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one;

where the compound is optionally as a pharmaceutically acceptable salt thereof.

43. (currently amended) The compound of Claim 16 selected from

40	(3 <i>Z</i> )-3-[(3-chlorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
41	(3 <i>Z</i> )-3-[(3-fluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
42	(3 <i>Z</i> )-3-[1 <i>H</i> -benzimidazol-2-yl(3,5-difluorophenyl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
48	(3 <i>Z</i> )-3-[(3-chlorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
53	(3 <i>Z</i> )-3-[(3-chloro-4-fluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
54	(3 <i>Z</i> )-3-[(3,4-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one

66	(3Z)-3-[(4-chlorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
73	(3Z)-3-[(3,5-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
74	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
75	(3Z)-3-[(3,5-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
76	(3Z)-3-[(3,5-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
79	(3Z)-3-[(3,4-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
80	(3Z)-3-[(3-chloro-4-fluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
91	(3Z)-3-[(4-chlorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl} amino)-1,3-dihydro-2 <i>H</i> -indol-2-one
102	(3Z)-3-[(4-chlorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
104	(3Z)-3-[(3,4-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
105	(3Z)-3-[(3-chloro-4-fluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
109	(3Z)-3-[(2,3-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
110	(3Z)-3-[(2,3-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
111	(3Z)-3-[(2,4-difluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
112	(3Z)-3-[(2,4-difluorophenyl)(1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one
118	(3Z)-3-[(4-chloro-2-fluorophenyl)(4-methyl-1 <i>H</i> -imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2 <i>H</i> -indol-2-one

where the compound is optionally as a pharmaceutically acceptable salt thereof.

44. **(previously presented)** The compound of Claim 39 named (3Z)-3-[(2-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-5-[(1-ethylpiperidin-4-yl)amino]-1,3-dihydro-2*H*-indol-2-one; where the compound is optionally as a pharmaceutically acceptable salt thereof.

45. **(previously presented)** The compound of Claim 39 named (3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(4-methyl-1*H*-imidazol-2-yl)methylidene]-1,3-dihydro-2*H*-indol-2-one; where the compound is optionally as a pharmaceutically acceptable salt thereof.

46. **(previously presented)** The Compound of Claim 1 selected from (3Z)-5-[(1-ethylpiperidin-4-yl)amino]-3-{1*H*-imidazol-2-yl}[6-(trifluoromethyl)pyridin-3-yl]methylidene}-1,3-dihydro-2*H*-indol-2-one and (3Z)-3-{1*H*-imidazol-2-yl}[6-(trifluoromethyl)pyridin-3-yl]methylidene}-5-({1-[2-(methyloxy)ethyl]piperidin-4-yl}amino)-1,3-dihydro-2*H*-indol-2-one; or a single geometric isomer thereof, optionally as a pharmaceutically acceptable salt thereof.

47. **(previously presented)** A pharmaceutical composition comprising a compound according to Claim 1, 9, 12, 13, 39, 40, 41, 42, 43, or 46 or a single stereoisomer, a single geometric isomer, a mixture of enantiomers, or a mixture of diastereomers thereof, where the compound is optionally as a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

48. **(previously presented)** A pharmaceutical composition comprising a compound according to Claim 44 or 45, where the compound is optionally as a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.